This pilot clinical trial studies how well positron emission tomography (PET)-dual-energy computed tomography (DECT) works in imaging for staging and treatment planning in patients with small cell lung cancer or non-small cell lung cancer. Diagnostic procedures, such as PET-DECT may help plan the best treatment for small cell or non-small cell lung cancer.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03146117.
PRIMARY OBJECTIVES:
I. To investigate the diagnostic performance of integrated fludeoxyglucose F-18 (FDG)-PET and DECT in determining the thoracic nodal status of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
II. To compare PET-CT and PET-DECT based planning in locally advanced SCLC and NSCLC for future guided research, in order to detect a potential difference in gross tumor volume (GTV) delineation.
III. To compare PET-CT and PET-DECT based planning in locally advanced SCLC and NSCLC for future guided research, in order to detect a potential difference in doses to normal structures including mean lung dose (MLD), volume of normal lung exceeding 20 Gy (V20) and mean esophageal dose (MED).
OUTLINE:
Patients receive fludeoxyglucose F-18 intravenously (IV) and undergo PET-DECT.
Trial PhaseNo phase specified
Trial Typediagnostic
Lead OrganizationMedical University of South Carolina
Principal InvestigatorCarlo De Cecco
